CommunicableDiseases

Community-acquired pneumonia is diagnosed by clinical features (e.g., cough, fever, pleuritic chest pain) and by lung imaging, usually an infiltrate seen on chest radiography. Initial evaluation should determine the need for hospitalization versus outpatient management using validated mortality or severity prediction scores. Selected diagnostic laboratory testing, such as sputum and blood cultures, is indicated for inpatients with severe illness but is rarely useful for outpatients. Initial outpatient therapy should include a macrolide or doxycycline. For outpatients with comorbidities or who have used antibiotics within the previous three months, a respiratory fluoroquinolone (levofloxacin, gemifloxacin, or moxifloxacin), or an oral beta-lactam antibiotic plus a macrolide should be used. Inpatients not admitted to an intensive care unit should receive a respiratory fluoroquinolone, or a beta-lactam antibiotic plus a macrolide. Patients with severe community-acquired pneumonia or who are admitted to the intensive care unit should be treated with a beta-lactam antibiotic, plus azithromycin or a respiratory fluoroquinolone. Those with risk factors for Pseudomonas should be treated with a beta-lactam antibiotic (piperacillin/tazobactam, imipenem/cilastatin, meropenem, doripenem, or cefepime), plus an aminoglycoside and azithromycin or an antipseudomonal fluoroquinolone (levofloxacin or ciprofloxacin). Those with risk factors for methicillin-resistant Staphylococcus aureus should be given vancomycin or linezolid. Hospitalized patients may be switched from intravenous to oral antibiotics after they have clinical improvement and are able to tolerate oral medications, typically in the first three days. Adherence to the Infectious Diseases Society of America/American Thoracic Society guidelines for the management of community-acquired pneumonia has been shown to improve patient outcomes. Physicians should promote pneumococcal and influenza vaccination as a means to prevent community-acquired pneumonia and pneumococcal bacteremia.  

This activity was developed for gastroenterologists, hepatologists, infectious disease (ID)/Human immunodeficiency virus (HIV) specialists, primary care physicians, and other healthcare providers managing patients with hepatitis C virus (HCV).  

Pick a category... Airway Management Cardiology Critical Care Critical Care Literature Update Dermatology Endocrine ENT Financial & Investing Gastrointestional Geriatrics Hematology/Oncology Infectious Disease International EM Med-Legal Medical Education Misc Neurology Obstetrics & Gynecology Ophthamology Orthopedics Pediatrics Pharmacology & Therapeutics Procedures Pulmonary Toxicology Trauma Urology Vascular Visual Diagnosis $('#pearl_categories').change(function(){ window.location = "/educational_pearls/search/?category=" + $(this).val() });  

Pick a category... Airway Management Cardiology Critical Care Critical Care Literature Update Dermatology Endocrine ENT Financial & Investing Gastrointestional Geriatrics Hematology/Oncology Infectious Disease International EM Med-Legal Medical Education Misc Neurology Obstetrics & Gynecology Ophthamology Orthopedics Pediatrics Pharmacology & Therapeutics Procedures Pulmonary Toxicology Trauma Urology Vascular Visual Diagnosis $('#pearl_categories').change(function(){ window.location = "/educational_pearls/search/?category=" + $(this).val() });  

A blood diagnostic kit that can detect infectious diseases such as HIV and hepatitis B in less than two hours won a European Inventor Award on Thursday for its developer.